NEC verwerft Noors Bio-informaticabedrijf, OncoImmunity AS
TOKYO-(BUSINESS WIRE)-NEC Corporation (NEC; TOKYO: 6701) kondigde vandaag de overname aan van OncoImmunity AS, een in Noorwegen gevestigd bio-informaticabedrijf dat eigen software voor machine learning ontwikkelt om de strijd tegen kanker te ondersteunen. OncoImmunity AS wordt nu een dochteronderneming van NEC en opereert onder de naam NEC OncoImmunity AS.
OncoImmunity AS, opgericht in 2014, is een bio-informaticabedrijf dat zich toelegt op de ontwikkeling van softwareoplossingen die de effectieve selectie van patiënten voor kankerimmunotherapie vergemakkelijken en optimale neo-antigeendoelen voor echt gepersonaliseerde kankervaccins en celtherapieën identificeren binnen een klinisch bruikbaar tijdsbestek.
NEC kondigde in mei 2019 zijn bedrijfsstrategie aan rond zijn AI-gedreven geneesmiddelenontdekkingsactiviteit. Deze overname is een integraal onderdeel van de verbetering van de middelen en capaciteiten die de ontwikkeling van zijn geïndividualiseerde immunotherapiepijplijnen ondersteunen.
NEC Acquires Norwegian Bioinformatics Company, OncoImmunity AS
TOKYO–(BUSINESS WIRE)– NEC Corporation (NEC; TOKYO: 6701) today announced the acquisition of OncoImmunity AS, a Norway-based bioinformatics company that develops proprietary machine learning software to support the fight against cancer. OncoImmunity AS will now become a subsidiary of NEC and operate under the name of NEC OncoImmunity AS.
OncoImmunity AS, founded in 2014, is a bioinformatics company dedicated to the development of software solutions that facilitate the effective selection of patients for cancer immunotherapy, and identify optimal neoantigen targets for truly personalized cancer vaccines and cell therapies in a clinically actionable time frame.
NEC announced its business strategy surrounding its AI-driven drug discovery business in May 2019. This acquisition is integral for enhancing the resources and capabilities that support the development of its individualized immunotherapy pipelines. NEC will maintain its focus on drug discovery, while NEC OncoImmunity AS continues its neoantigen prediction services.
Sharing a common vision, both NEC and OncoImmunity AS firmly believe in improving individualized cancer treatments through Artificial Intelligence (AI). AI holds great promise in enabling each and every patient to receive the most appropriate medication.
“The OncoImmunity AS team are delighted to be joining the NEC Group and firmly believe that the union will realize great synergies, marrying the mutual strengths of OncoImmunity AS’s and NEC’s neoantigen prediction pipelines with NEC’s expertise in AI, data management and security. These synergies will help strengthen NEC’s individualized immunotherapy programs, whilst simultaneously positioning NEC OncoImmunity AS as the leading neoantigen prediction service provider in the field,” said Dr. Richard Stratford, Chief Executive Officer and Co-founder of OncoImmunity AS.
“NEC strongly believes that healthcare based on genomics paves the way for individualized medicine. OncoImmunity AS is a recognized player in the neoantigen prediction field, and their compelling systems are expected to form valuable synergies with NEC. We are confident that this acceleration of development will provide promising new avenues that lead to better cancer treatments,” said Osamu Fujikawa, Senior Vice President, NEC Corporation.
About NEC Corporation
For more information, visit NEC at http://www.nec.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20190729005230/en/
Contacts
NEC Corporation
Joseph Jasper
Corporate Communications Division
j-jasper(at)ax.jp.nec.com
Check out our twitter: @NewsNovumpr